Login / Signup

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

A H BryceJ J AlumkalAndrew J ArmstrongC S HiganoP IversenC N SternbergD RathkopfY LoriotJohann S de BonoB TombalS AbhyankarP LinA KrivoshikD PhungT M Beer
Published in: Prostate cancer and prostatic diseases (2017)
Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with enzalutamide. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • squamous cell carcinoma
  • high resolution
  • small cell lung cancer